| Description | Ociperlimab, a humanized IgG1 anti-TIGIT antibody, exhibits high affinity for the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. It effectively inhibits the interaction between TIGIT and its ligands PVR or PVR-L2, and is utilized in cancer research [1] [2]. |
| In vitro | Ociperlimab（BGB-A1217；0-10 μg/mL）能够提升巨细胞病毒特异性T细胞分泌IFN-γ的能力[1]。在1-1000 ng/mL的浓度范围内，Ociperlimab通过Fc依赖性机制活化自然杀伤细胞与单核细胞[1]。此外，Ociperlimab能够在体外通过Fc依赖性内吞作用，从T细胞表面清除TIGIT[1]。 |
| In vivo | Ociperlimab（BGB-A1217；剂量为3和10 mg/kg；通过腹腔注射给药；在CT26 WT和MC38荷瘤的人源化TIGIT敲入小鼠模型中）通过Fc功能展现出其抗肿瘤效能[1]。 |
| Synonyms | BGB-A1217 |
| molecular weight | N/A |
| CAS | 2342597-93-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |